Description
Clemizole inhibits transient receptor potential cation 5 (TRPC5) channels. Clemizole also suppresses replication of hepatitis C virus (HCV) by inhibiting NS4B activity. This compound displays a wide variety of biological activities, including antiviral, anticonvulsant, antiepileptic, and anti-allergic properties. In vivo, clemizole prevents the development of seizures and decreases convulsive behaviors. This compound also may inhibit histamine H1 receptors, suppressing histamine activity.
References
Richter JM, Schaefer M, Hill K. Clemizole hydrochloride is a novel and potent inhibitor of transient receptor potential channel TRPC5. Mol Pharmacol. 2014 Nov;86(5):514-21. PMID: 25140002.
Baraban SC, Dinday MT, Hortopan GA. Drug screening in Scn1a zebrafish mutant identifies clemizole as a potential Dravet syndrome treatment. Nat Commun. 2013;4:2410. PMID: 24002024.
Einav S, Sobol HD, Gehrig E, et al. The hepatitis C virus (HCV) NS4B RNA binding inhibitor clemizole is highly synergistic with HCV protease inhibitors. J Infect Dis. 2010 Jul 1;202(1):65-74. PMID: 20486856.
